Posters

iStent inject as stand-alone procedure in phakic open angle glaucoma: first clinical annual results

Poster Details

First Author: M. Klamann GERMANY

Co Author(s):    J. Gonnermann   M. Pahlitzsch   A. Maier   N. Torun   E. Bertelmann        

Abstract Details

Purpose:

The effectiveness of the iStent inject implantation among different phakic open angle glaucoma subgroups was analyzed over 1 year.

Setting:

Department of Ophthalmology, University Medicine Charité Berlin, Berlin, Germany.

Methods:

In this retrospective cohort outcome study, 27 consecutive phakic patients suffering from glaucoma (primary open angle glaucoma (POAG) N = 16; exfoliative glaucoma (XFG) N = 11) were treated with the iStent inject as a stand-alone procedure. The intraocular pressure (IOP) and the number of antiglaucoma medication before and after surgery were evaluated.

Results:

In POAG, a significant IOP reduction of 33% to 14.1 mmHg ±1.7 from preoperative IOP to 1 year follow-up time was present (p<0.001). In XFG, the IOP measured 16.5 ± 2.7 mmHg after 1 year with an average decrease of 26% from preoperative IOP (p<0.001). The number of antiglaucoma medication decreased from 2.2 ± 0.9 to 1.6 ± 1.2 in POAG (p=0.104) and from 2.3 ± 1.2 to 2.01 ± 1.6 in XFG (p=0.140) after 1 year.

Conclusions:

In conclusion, implantation of the iStent inject as a stand-alone procedure has the ability to lower the postoperative IOP significantly in phakic POAG and XFG after 1 year.

Financial Disclosure:

NONE